Diker Management LLC Acquires 3,000 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Diker Management LLC increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 57.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,222 shares of the medical equipment provider’s stock after acquiring an additional 3,000 shares during the quarter. Lantheus accounts for approximately 0.6% of Diker Management LLC’s portfolio, making the stock its 25th largest position. Diker Management LLC’s holdings in Lantheus were worth $736,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of LNTH. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after purchasing an additional 3,772 shares during the period. Empirical Asset Management LLC acquired a new stake in Lantheus in the fourth quarter valued at approximately $323,000. Focus Financial Network Inc. bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $292,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Lantheus by 12.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider’s stock worth $13,006,000 after purchasing an additional 16,466 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new stake in Lantheus in the 3rd quarter valued at $60,000. 99.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of recent research reports. Truist Financial raised their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, B. Riley dropped their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $134.33.

Lantheus Stock Down 23.2 %

Lantheus stock opened at $80.53 on Thursday. The company’s 50 day moving average price is $100.19 and its two-hundred day moving average price is $94.79. Lantheus Holdings, Inc. has a 52 week low of $74.28 and a 52 week high of $126.89. The stock has a market cap of $5.51 billion, a P/E ratio of 13.40 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.69 earnings per share. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock worth $6,016,046 over the last three months. 2.00% of the stock is currently owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.